Tenuigenin ameliorates Alzheimer’s disease by targeting MAP2K1: integrated evidence from network pharmacology and experimental validation

Chunyu Fu, Yuna Kan, Kedong Guo, Liyan Jiang, Yingbo Zhang, Haiying Dong, Jiaming Xie

Open source

DOI: 10.1097/wnr.0000000000002239
Published: 2025-12-23
Container: NeuroReport
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/wnr.0000000000002239,
  title = {Tenuigenin ameliorates Alzheimer’s disease by targeting MAP2K1: integrated evidence from network pharmacology and experimental validation},
  author = {Chunyu Fu and Yuna Kan and Kedong Guo and Liyan Jiang and Yingbo Zhang and Haiying Dong and Jiaming Xie},
  year = {2025},
  journal = {NeuroReport},
  doi = {10.1097/wnr.0000000000002239},
  url = {https://doi.org/10.1097/wnr.0000000000002239}
}

RIS

TY  - JOUR
TI  - Tenuigenin ameliorates Alzheimer’s disease by targeting MAP2K1: integrated evidence from network pharmacology and experimental validation
AU  - Chunyu Fu
AU  - Yuna Kan
AU  - Kedong Guo
AU  - Liyan Jiang
AU  - Yingbo Zhang
AU  - Haiying Dong
AU  - Jiaming Xie
PY  - 2025
JO  - NeuroReport
DO  - 10.1097/wnr.0000000000002239
UR  - https://doi.org/10.1097/wnr.0000000000002239
ER  -

APA

Fu, C., Kan, Y., Guo, K., Jiang, L., Zhang, Y., Dong, H., & Xie, J. (2025). Tenuigenin ameliorates Alzheimer’s disease by targeting MAP2K1: integrated evidence from network pharmacology and experimental validation. NeuroReport. https://doi.org/10.1097/wnr.0000000000002239

Source records

crossref · retrieved 2026-09-27T14:36:48.411Z